From Analysis:
Does Alectinib truly bind C1q directly with high affinity, or is this an experimental artifact?
The fundamental premise remains unvalidated despite extensive mechanistic speculation. Independent validation using purified proteins and orthogonal binding assays is essential before pursuing mechanistic studies. This determines whether any C1q-related effects are direct or indirect. Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e (Analysis: SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e)
Alectinib may block complement receptor 3 (CR3, encoded by ITGAM/CD11b) function on microglia, reducing recognition and engulfment of C1q-opsonized synapses without directly binding C1q. Genetic loss-of-function studies in mice demonstrate that both C1qa-/- and Itgam-/- impair postinjury debris clearance, establishing a functional C1q-CR3 axis (PMID: 29941548). Pharmacologic CR3 blockade reduces phagocytic microglia and early synapse loss, consistent with CR3 involvement in complement-mediated synaptic pruning (PMID: 27033548). This remains an actionable hypothesis because ITGAM/CD11b sits close to the synapse-pruning effector step, and the C1q-CR3 axis represents a proximal mechanism by which alectinib could interrupt synaptic engulfment.
...No AI visual card yet
Mechanism: C1q binds directly to disease-altered N-glycans or O-glycans on myelin debris, apoptotic neurites, or synaptic membranes, while a separate C1q domain engages microglial lectin receptors such as CLEC7A, SIGLEC11, or SIGLEC3/CD33. In this model, C1q effects that appear receptor-specific are actually ternary-complex effects requiring both purified C1q and a glycosylated ligand surface.
Key Evidence: C1q recognizes diverse altered-self ligands on apoptotic cells and immune complexes through its globular heads, supporting multivalent pattern-rec
The hypothesis requires C1q to possess two functionally distinct binding domains: one for disease-altered glycans on target surfaces and a separate, unspecified domain engaging microglial lectin receptors (SIGLEC3/CD33, CLEC7A, SIGLEC11). C1q's structure is well-characterized—globular heads mediate target recognition while collagen-like stalks engage complement receptors (CR1, CR2) and FcγRs. **There is no validated lectin-bind
The Skeptic's fundamental challenge is well-founded: pursuing mechanistic studies on unvalidated premises risks wasted resources and misleading therapeutic leads. However, translational potential depends not only on mechanistic validity but also on the existence of druggable targets, patient population fit, and synergy with the current clinical development landscape.
{
"ranked_hypotheses": [
{
"rank": 1,
"title": "ApoE-Isoform C1q Scaffold Hypothesis",
"mechanism": "ApoE isoforms serve as scaffolds that differentially modulate C1q deposition on lipid surfaces, altering complement activation patterns and microglial recognition.",
"target_gene": "APOE",
"confidence_score": 0.8,
"novelty_score": 0.5,
"feasibility_score": 0.6,
"impact_score": 0.8,
"composite_score": 0.68,
"testable_prediction": "SPR or co-immunoprecipitation assays comparing ApoE2/E3/E4 isoforms will reveal isoform-specific di
No knowledge graph edges recorded
molecular biology | 2026-04-21 | completed
No comments yet. Be the first to comment!